Immix Biopharma (IMMX) Cash from Investing Activities (2021 - 2026)
Immix Biopharma's (IMMX) quarterly Cash from Investing Activities came in at -$4.8 million in Q1 2026, down 6989.98% year-on-year from $69678.6 in Q1 2025, and up 27.76% quarter-over-quarter from -$6.6 million in Q4 2025.
Immix Biopharma (IMMX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Immix Biopharma has disclosed Cash from Investing Activities across 5 years of filings, most recently posting -$4.8 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$4.8 million, down 6989.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.9 million (down 1166.26% YoY), and the FY2025 annual result was -$7.2 million, down 512.54% from the prior year.
- Cash from Investing Activities came in at -$4.8 million for Q1 2026 at Immix Biopharma, up from -$6.6 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$13177.0 in Q4 2023 to a low of -$6.6 million in Q4 2025.
- The 4-year median for Cash from Investing Activities is -$286727.5 (2024), against an average of -$1.3 million.
- Across the five-year window, Cash from Investing Activities soared 77.57% in 2025 and sank 6989.98% in 2026, its largest moves.
- Immix Biopharma's Cash from Investing Activities stood at -$13177.0 in 2023, then plunged by 3748.76% to -$507151.0 in 2024, then slumped by 1210.46% to -$6.6 million in 2025, then climbed by 27.76% to -$4.8 million in 2026.
- The last three Cash from Investing Activities figures came in at -$4.8 million (Q1 2026), -$6.6 million (Q4 2025), and -$372456.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - | -4.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.80 Mn |
| Mar 31, 2026 | -4.80 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -372,456.00 |
| Sep 30, 2025 | -372,456.00 |
| Jun 30, 2025 | -127,630.00 |
| Jun 30, 2025 | -127,630.00 |
| Mar 31, 2025 | -67,713.00 |
| Mar 31, 2025 | -67,713.00 |
| Dec 31, 2024 | -507,151.00 |
| Dec 31, 2024 | -507,151.00 |
| Sep 30, 2024 | -271,542.00 |
| Sep 30, 2024 | -271,542.00 |
| Jun 30, 2024 | -97,074.00 |
| Jun 30, 2024 | -97,074.00 |
| Mar 31, 2024 | -301,913.00 |
| Mar 31, 2024 | -301,913.00 |
| Dec 31, 2023 | -13,177.00 |
| Dec 31, 2023 | -13,177.00 |